Intrasense — Regulatory Filings 2017

Nov 27, 2017

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions, will provide Myrian® as a pedagogical tool for the "Prostate MRI" workshop at RSNA 2017, international reference congress of radiology.

Internationally renowned teachers will guide the trainees - 500 radiologists about the MRI reference method PI-RADS 2, using Myrian® XP-Prostate software.

This workshop, a first for Intrasense, will benefit from high exposure from November 26 to December 1, in the Radiological Society of North America Congress (RSNA), the largest radiology congress worldwide, bringing together in Chicago radiologists from 136 countries.

The several sessions of the "Prostate MRI" workshop will review multiparametric cases with the MRI Prostate Imaging Reporting and Data System (PI-RADS 2) method, available within Myrian® prostate module.

PI-RADS 2 is a world-reference methodology for MRI, a key contribution to a better efficiency in sharing of information in the chain of care of prostate treatment.

This method optimizes patient management and follow-up by enabling physicians to score the probability of the presence of a prostate cancer in patients, with optimized recognition and differentiation from benign pathology.

Two men out of nine will develop a clinical form of prostate cancer in their lifetime. Second most frequent cancer for men in the world, prostate cancer affects more than 1.1 million cases and will increase by +75% by 2030 (source: WHO - 2012). It represents a real challenge for MRI detection, requiring adapted tools, such as Intrasense's Myrian® XP-Prostate software, with well-trained qualified users.

"We are really honored that Myrian® has been the selected solution for this reference and large audience scientific workshop. Since its creation, Myrian® XP-Prostate integrates the PI-RADS scoring mechanism, giving easy access to structured reports with localization diagrams, providing valuable information to clinicians." comments Philippe MICHELON, Product Director at Intrasense.

Founded in 2004, Intrasense develops and markets a unique medical device called Myrian®, a software platform that facilitates diagnosis, decision-making and therapeutic follow-up and makes them more secure. Thanks to Myrian®, more than 800 health institutions spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner…). Enriched with expert clinical modules dedicated to specific pathologies, Myrian® also provides a universal image treatment solution that can be fully integrated in any health information system. Intrasense includes 45 employees among which 20 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and invested more than 10 million euros in Research & Development since its creation.

For more information, please visit www.intrasense.fr.

Intrasense Stéphane Chemouny Chairman and Chief Executive Officer Christophe Lamboeuf Deputy Managing Director Tel: +33 4 67 130 130 investor@intrasense.fr

NewCap Investor Relations and Financial Communication Valentine Brouchot Pierre Laurent Tel: + 33 1 44 71 94 96 intrasense@newcap.eu